<DOC>
	<DOC>NCT01966419</DOC>
	<brief_summary>The purpose of this study is to determine whether ornithine phenylacetate can speed recovery from an acute hepatic encephalopathy episode requiring hospitalization in cirrhotic patients.</brief_summary>
	<brief_title>Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)</brief_title>
	<detailed_description>This is a multicenter, randomized, double-blind, placebo-controlled study of ornithine phenylacetate (OCR-002) administered intravenously to hospitalized patients with cirrhosis, hyperammonemia, and an acute episode of hepatic encephalopathy administered on top of standard of care treatment.</detailed_description>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Hepatic Encephalopathy</mesh_term>
	<mesh_term>Hyperammonemia</mesh_term>
	<mesh_term>Phenylacetic acid</mesh_term>
	<criteria>Hospitalized with an acute episode of hepatic encephalopathy as complication of cirrhosis Elevated venous ammonia Renal failure with serum creatinine &gt; 3 mg/dL or need for dialysis Molecular Adsorbent Recirculation System utilized Pregnancy or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>hepatic encephalopathy</keyword>
	<keyword>hyperammonemia</keyword>
	<keyword>cirrhosis</keyword>
	<keyword>ornithine phenylacetate</keyword>
	<keyword>OCR-002</keyword>
</DOC>